The Wall Street star went public with his HIV positive status in November last year (15), announcing that he had been diagnosed with the virus in 2011.
In January (16), Charlie announced he had stopped taking the medication designed to prevent his condition progressing to Acquired Immune Deficiency Syndrome (AIDS), the deadly phase of the disease, in favour of alternative medicine.
However, the star says he is now part of an American clinical trial which sees him receive an injection of PRO 140, a new drug designed to prevent the virus infecting healthy cells, and as a result his health is improving.
“I’m actually involved in a FDA (America's Food and Drug Administration) trial where it’s going to change the immediate landscape of HIV treatment," he tells Britain's i newspaper. "It’s a company called CytoDyn and a treatment called PRO 140. And instead of taking the pills every day, it’s one shot every week.
“So I go to my doctor and he administers that. I’m in my third week of that and I already feel amazing, because taking those pills every day, it’s a bit toxic you know. This is quite the opposite, so we’re really excited about the prospect of that."
Arch Therapeutics ($ARTH) is a Wellesley, MA, bulletin-board biotech that has traded since late 2012. Arch shares are also traded on the Berlin exchange. ARTH’s lead product, a liquid called AC5, is being advanced as something more like a medical device than a drug. It is a clear, colorless, non-viscous watery liquid that, in the presence of ions, rapidly forms durable two-dimensional barriers. AC5 acts as an in vivo Saran wrap that seals wounds, but doesn’t do so by triggering clotting. All bodily fluids have positive- and negative-charge-bearing ions, and in fact fresh surgical wounds often transiently bear charges because of how mechanical trauma disrupts cell membranes. Such charges cause protein strands in AC5 to anneal, to line up and aggregate, but to do so primarily in two dimensions, not three. Sealant sheets are formed instead of glue-like globs. I’ll declare it loud and clear: I have read many papers on the actions of AC5 and seen video footage of it being used in animal surgery, and it is the most impressive idea and product I have ever seen in 20 years of biotech investing. It seals wounds and halts bleeding and oozing within seconds, even when the animal is on blood thinner. It could halve surgical times, as an average operation has the surgeon spending half his time addressing bleeding (some forms of surgery, such as orthopedic procedures and liver surgery, are even more bloodletting). It could slash operating room times and the need for perioperative blood transfusion.
The insiders are more the story for Arch Therapeutics than the proposed product they are developing. While Terrence W. Norchi, M.D. takes the spotlight as President and CEO of the company he co-founded in 2006, Avtar Dhillon, M.D. comes with the real resume traders want to see.
Dr. Dhillon, 52, has been a member of the Board of Directors of Arch Therapeutics since May 2011. Dr. Dhillon is the former President & CEO of Inovio Pharmaceuticals, Inc. (AMEX: INO). During his tenure at Inovio, nearly a decade, Dr. Dhillon successfully led the turnaround of the company through restructuring and acquisition of technology from several European and North American companies including merger with VGX Pharmaceuticals to develop a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Additionally, $136 million in financing was arranged during his tenure as well as several licensing deals valued at over $200 million that has included global giants, Merck and Wyeth (now Pfizer).
But wait, it gets even better….
In addition to his current board member roles with Arch Therapeutics, OncoSec Medical Inc. (ONCS)(Chairman), Inovio (INO)(Chairman) and Stevia First, Corp. (STVF)(Chairman), Dr. Dhillon currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.